Sign in
Taking peopleNo phase

Heart Rate Variability in Early Prediction of a Noxic Brain Injury After Cardiac Arrest

Key facts

Who runs it
CMC Ambroise Paré
Where
France5 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
200 people, planned
Started
23 Oct 2024
Expected to end
15 Dec 2027
Type of study
Observational
Treatments tested
  • 24-hour Holter monitoring
Record updated
16 December 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Admitted in intensive care unit (ICU) after resuscitation from cardiac arrest (in-hospital or out-of-hospital)
  • Coma (Glasgow score < 8) after ROSC, requiring sedation and targeted temperature management for at least 24h

Who cannot take part

  • Dying patient (Limitation of life support techniques at admission to the ICU)
  • Non-Sinus Rhythm
  • Pregnant or breastfeeding women
  • Patient under protection of the adults (guardianship, curators or safeguard of justice)
  • Opposition by the trusted person or by the patient once he/she wakes up

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Despite advances in post-resuscitation care of patients with cardiac arrest (CA), the majority of survivors who are treated after restoration of spontaneous circulation (ROSC) will have sequelae of hypoxic-ischemic brain injury ranging from mild cognitive impairment to a vegetative state.

Read full original descriptionShow less

Early prognostication in comatose patients after ROSC remains challenging. Recent recommendations suggest carrying out clinical and paraclinical tests during the first 72 h after ROSC, to predict a poor neurological outcome with a specificity greater than 95% (no pupillary and corneal reflexes, bilaterally absent N20 somatosensory evoked potential wave, status myoclonus, highly malignant electroencephalography including suppressed background ± periodic discharges or burst-suppression, neuron-specific enolase (NSE) > 60 µg/L, a diffuse and extensive anoxic injury on brain CT/MRI), but with a low sensitivity due to frequent confounding factors.

The heart rate variability (HRV) is a simple and non-invasive technique for assessing the autonomic nervous system function. In patients with a recent myocardial infarction, reduced HRV is associated with an increased risk for malignant arrhythmias or death. In neurology, reduced HRV is associated with a poor outcome in severe brain injury patients and allows to predict early neurological deterioration and recurrent ischemic stroke after acute ischemic stroke.

A reduced HRV could be a sensitive, specific and early indicator of diffuse anoxic brain injury after CA.

This multicenter prospective cohort study assesses the added value of early HRV (within 24h of ICU admission) for neuroprognostication after cardiac arrest.

The group in the trial

  • Post-cardiac arrest patients

    Treatment: 24-hour Holter monitoring

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
16 December 2024